TABLE 1.

Non‐comprehensive list of ongoing CAR T cell therapy studies in solid organ malignancies^*

Cancer type	NCT number	Recruiting status	Brief title	Cell target
Brain Cancers (Glioblastoma)	NCT02208362	Ongoing Phase I	Genetically Modified T‐cells in Treating Patients with Recurrent or Refractory Malignant Glioma	IL13Ra2
	NCT03726515	Ongoing Phase I	CART‐EGFRvIII + Pembrolizumab in GBM	EGFRvIII
	NCT01454596	Completed recruiting/ phase I	CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients with Malignant Gliomas Expressing EGFRvIII	EGFRvIII
	NCT01109095	Completed recruiting/ phase I	CMV‐specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM	HER2
Gastrointestinal Cancers	NCT01373047	Completed recruiting/ phase I	CEA‐Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti‐CEA Designer T Cells	CEA
	NCT03682744	Ongoing phase I	CAR‐T Intraperitoneal Infusions for CEA‐Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)	CEA
	NCT01897415	Completed recruiting/ phase I	Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer	Mesothelin
	NCT03323944	Ongoing phase I	CAR T Cell Immunotherapy for Pancreatic Cancer	Mesothelin
	NCT03159819	Ongoing phase I	Clinical Study of CAR‐CLD18 T Cells in Patients with Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma	Claudin 18.2
	NCT02744287	Ongoing phase I	Safety and Activity Study of PSCA‐Targeted CAR‐T Cells (BPX‐601) in Subjects with Selected Advanced Solid Tumors	PSCA
Renal Cancer	N/A	Preclinical		Carboxy‐anhydrase IX (CAIX)
	NCT03393936	Ongoing phase I	Safety and Efficacy of CCT301 CAR‐T in Adult Subjects with Recurrent or Refractory Stage IV Renal Cell Carcinoma	AXL
Prostate Cancer	NCT03089203	Ongoing phase I	CART‐PSMA‐TGFβRDN Cells for Castrate‐Resistant Prostate Cancer	PSMA
	NCT03873805	Ongoing phase I	PSCA‐CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer	PSCA
Ovarian Cancer	NCT03585764	Ongoing phase I	MOv19‐BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Folate receptor‐alpha
	NCT02498912	Ongoing phase I	Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL‐12 and to Target the MUC16ecto Antigen in Patients with Recurrent MUC16ecto+ Solid Tumors	MUC16
	NCT02792114	Ongoing phase I	T‐Cell Therapy for Advanced Breast Cancer	Mesothelin
	NCT02442297	Ongoing phase I	T Cells Expressing HER2‐specific Chimeric Antigen Receptors (CAR) for Patients with HER2‐Positive CNS Tumors	HER2
	NCT03696030	Ongoing phase I	HER2‐CAR T Cells in Treating Patients with Recurrent Brain or Leptomeningeal Metastases	HER2
	NCT04020575	Ongoing phase I	Autologous huMNC2‐CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1	MUC1
Thoracic Cancer	NCT02414269	Ongoing phase 1	Malignant Pleural Disease Treated with Autologous T Cells Genetically Engineered to Target the Cancer‐Cell Surface Antigen Mesothelin	Mesothelin
	NCT0305429	Ongoing phase 1	CAR T Cells in Mesothelin Expressing Cancers	Mesothelin
	NCT02706392	Ongoing phase 1	Genetically Modified T‐Cell Therapy in Treating Patients with Advanced ROR1+ Malignancies	ROR1

^*Last updated on 09/29/ 2021 from clinicaltrials.gov.